HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tomoko Kohda Selected Research

Neurotoxins

10/2022A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA.
11/2013Botulinum neurotoxin A2 reduces incidence of seizures in mouse models of temporal lobe epilepsy.
3/2013Improved detection methods by genetic and immunological techniques for botulinum C/D and D/C mosaic neurotoxins.
11/2010In vivo molecular imaging analysis of a nasal vaccine that induces protective immunity against botulism in nonhuman primates.
1/2010Characterization of the D/C mosaic neurotoxin produced by Clostridium botulinum associated with bovine botulism in Japan.
2/2007Differential contribution of the residues in C-terminal half of the heavy chain of botulinum neurotoxin type B to its binding to the ganglioside GT1b and the synaptotagmin 2/GT1b complex.
4/2006Protective effect of botulinum C/D mosaic toxoid against avian botulism.
9/2005Characterization of the neurotoxin produced by isolates associated with avian botulism.
1/2003Sequence of the gene for Clostridium botulinum type B neurotoxin associated with infant botulism, expression of the C-terminal half of heavy chain and its binding activity.
10/2002Characterization of Clostridium butyricum neurotoxin associated with food-borne botulism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tomoko Kohda Research Topics

Disease

17Botulism
07/2020 - 10/2002
2Edema Disease of Swine
12/2021 - 11/2014
2Infections
08/2016 - 06/2012
2Paralysis (Palsy)
01/2015 - 04/2012
2Parkinson Disease (Parkinson's Disease)
08/2014 - 05/2014
1Severe Acute Respiratory Syndrome
11/2023
1Paresis (Hemiparesis)
10/2022
1Stroke (Strokes)
10/2022
1Muscle Spasticity (Spastic)
10/2022
1Serum Sickness
01/2020
1Anaphylaxis (Anaphylactic Shock)
01/2020
1Enzootic Bovine Leukosis (Bovine Leukosis)
08/2016
1Inflammation (Inflammations)
01/2015
1Otitis Externa
01/2015
1Edema (Dropsy)
11/2014
1Temporal Lobe Epilepsy
11/2013
1Seizures (Absence Seizure)
11/2013
1Communicable Diseases (Infectious Diseases)
07/2010
1Epilepsy (Aura)
08/2009
1Diphtheria
03/2008

Drug/Important Bio-Agent (IBA)

10NeurotoxinsIBA
10/2022 - 10/2002
9Botulinum Toxins (Botulinum Toxin)IBA
10/2022 - 08/2009
4AntitoxinsIBA
11/2012 - 09/2005
4VaccinesIBA
06/2012 - 02/2005
3Type A Botulinum Toxins (Botox)FDA Link
10/2022 - 05/2014
3incobotulinumtoxinAFDA Link
08/2014 - 05/2010
2Shiga Toxin (Shigella Toxin)IBA
12/2021 - 11/2014
2Neurotransmitter Agents (Neurotransmitter)IBA
01/2015 - 04/2012
2Phospholipase DIBA
01/2015 - 03/2008
1Messenger RNA (mRNA)IBA
11/2023
1Neutralizing AntibodiesIBA
01/2020
1AntibodiesIBA
01/2020
1Biomarkers (Surrogate Marker)IBA
08/2016
1DNA (Deoxyribonucleic Acid)IBA
08/2016
1Virulence Factors (Pathogenicity Factors)IBA
01/2015
1Phospholipases (Phospholipase)IBA
01/2015
1IgYIBA
11/2014
1Immunoglobulins (Immunoglobulin)IBA
11/2014
1Proteins (Proteins, Gene)FDA Link
05/2014
1Acetylcholine (Acetylcholine Chloride)FDA Link
05/2014
1Indicators and Reagents (Reagents)IBA
11/2013
1Anticonvulsants (Antiepileptic Drugs)IBA
11/2013
1ConvulsantsIBA
11/2013
1AntigensIBA
07/2010
11-dodecylpyridoxal (PLD)IBA
03/2008
1Amino AcidsFDA Link
02/2007
1ToxoidsIBA
04/2006

Therapy/Procedure

1Injections
11/2013